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Abstract 
 
The preparation and application of groups of new iridium complexes are described.  In 
particular, iridium complexes possessing phosphine ligands and a bulky N-heterocyclic 
carbene have been shown to be robust and readily handled species and have been applied 
in a range of directed hydrogen-deuterium and –tritium exchange processes and, in 
particular, with drug-like substrates or within ADMET-related studies. Overall, these 
new iridium(I) complexes are shown to be highly active catalysts and display catalytic 
activity far in excess of the industry standard, Crabtree’s catalyst, with excellent levels 
of labelling being achieved over short reaction times and at low metal complex loadings, 
whilst tolerating a wide range of functional moieties.  Furthermore and again in contrast 
to systems employing Crabtree’s catalyst, the low catalyst loadings and short reaction 
times made possible by these emerging iridium carbene comple have delivered tritiated 
products with very good levels of labelling and without any appreciable by-product 
waste production. 
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Introduction 
 
Attrition, or high failure rate, has emerged as a central problem within modern drug 
development.  In relation to this, the design of medicinal agents, with optimal potency 
and pharmacokinetic properties, as well as an increased safety profile, poses a major 
challenge within pharmaceutical laboratories.  Consequently, this has elevated the 
importance of and, in turn, created requirements for faster absorption, distribution, 
metabolism, excretion and toxicology (ADMET) methods and, therefore, for more 
extensive use of radiolabelled compounds.  To meet these demands, the development of 
new and more efficient hydrogen isotope labelling techniques is essential. 
 
One of the most effective ways to follow drug metabolism is to use site-specific 
labelling, most conveniently with a heavy isotope of hydrogen or carbon.  Within the 
field of hydrogen isotope exchange (HIE) the ideal situation would be to utilise sub-
stoichiometric quantities of a catalyst to carry out the required transformation on a fully 
functionalised target molecule.  In this regard, C-H activation using organometallic 
species has grown to become an area of widespread significance in organic synthesis and 
ortho-C-H activation (Scheme 1) has been particularly important as part of HIE 
endeavours. 
 
 
 
Scheme 1.  Ideal hydrogen isotope exchange process. 
 
Crabtree’s catalyst (1, Figure 1),1 designed originally for the hydrogenation of olefinic 
double bonds, is by far the most widely used species in HIE labelling.  In relation to this, 
the isotopic incorporation and ortho-regioselectivity is high for a wide variety of 
molecules possessing low to medium complexity.2  However, the scope of 1 is limited 
by a number of factors.  First of all, dichloromethane (DCM) is usually the only solvent 
that is tolerated with this catalyst.  In addition, bulky substituents in the vicinity of the 
targeted hydrogen unit inhibit exchange; inactive iridium dimers and trimers are known 
to form in solution, particularly when directing unit complexation is hindered; and some 
functional groups do not deliver any appreciable degree of labelling.3,4  Furthermore and 
perhaps most importantly in a practical sense, high loadings of Crabtree’s catalyst 1 (i.e. 
equimolar or higher) are often required to deliver effective levels of exchange, due to 
unproductive complexation with non-directing substituents within a given molecule.  
Consequently and with specific regard to tritiation processes, these high metal complex 
loadings lead to large amounts of volatile labelled cyclooctane and/or cyclooctene as 
undesirable by-products.  Such radioactive by-product formation can be prevented by 
pre-activation of the catalyst with hydrogen,5 however this introduces an extra step 
within the overall practical process and leads to a less straightforward labelling 
procedure. 
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Figure 1.  Crabtree’s catalyst. 
 
The literature in the area of directed HIE overall is well covered both in this current 
edition of the journal and in a previous special edition in memoriam of John R. Jones.6  
The HIE reaction and other labelling techniques have recently been reviewed,7,8 with a 
range of complexes of Pt, Rh, Ru, and Ir having been explored most widely.  More 
specifically, a good number of independent research teams, particularly within the 
pharmaceutical industry, have further developed and used HIE processes with Ir(I) 
complexes.  For example, Heys describes the employment of Raman spectroscopy for 
monitoring tritiation within such HIE (and related) reactions.9  A recent publication also 
describes meta-substituent effects on organoiridium-catalysed ortho-hydrogen isotope 
exchange and a new mechanistic route for the HIE reaction.10  Crabtree’s complex 1 has 
also been utilised in conjunction with rhodium black to improve the activity of this 
catalyst species.11  An alternative iridium(I) system,12 which can be utilised in DMF or 
DMA, has also been developed and is useful for certain functional groups where the 
common industrial practice13 of utilising 1 in dichloromethane is impractical.  It should 
also be noted that the limited diversity of solvents that can be used in conjunction with 
Crabtree’s catalyst 1 is often a drawback and limits the scope of such methods, since 
many potential drug candidates are insoluble in DCM.  The use of ionic liquids is one 
solution but the levels of incorporation into substrates of somewhat elevated polarity 
remain only moderate.14  Another problem is the formation of catalyst-derived labelled 
impurities, although this can be somewhat avoided by the use of a polymer-supported 
solid phase Ir(I) catalyst.15  In addition to ortho-exchange, labelling into suitably 
positioned methyl or methylene units13 has been known since the early days of the HIE-
technique.16   
 
 
Pincer Complexes 
 
In efforts to expand the HIE-area, research within the AstraZeneca R&D laboratories, 
Mölndal, investigated whether new Ir(III) complexes could be applied effectively, 
especially relative to 1.  The initial approach was based on the preparation of novel 
pincer complexes.  Such species possess a tridentate, so-called, pincer ligand around a 
metal centre.17,18  In relation to this, Moulton and Shaw reported pioneering work on the 
synthesis of iridium PCP-pincers in the mid-1970’s.19  This work prompted the research 
groups of Kaska and Jensen,20 Goldman,21 Leitner,22 and Brookhart23 to investigate 
their use as catalysts for the dehydrogenation of hydrocarbons.  Hartwig has also 
reported the application of iridium PCP-pincers for N-H activation in ammonia.24  The 
possibility to tune the electronic and steric properties of the pincer ligand, combined with 
the strong coordination of the iridium atom within a PCP-pincer complex (Figure 2), 
prompted us to investigate their ability to catalyse HIE. 
 
 
 
Figure 2.  Tuneable sites of an Ir(III)-PCP-pincer complex. 
 
Based on this rationale, we prepared a small series of novel iridium-pincer complexes,25 
with Leitner divulging details of a ruthenium-pincer complex for use in HIE reactions at 
around the same time.26  Whilst our Ir species showed some good to moderate activity 
in directed deuterations with a small selection of substrates, these Ir-pincer complexes 
did not enhance the HIE processes in a general sense when compared to Crabtree’s 
catalyst 1.  Accordingly, we did not pursue this area further at this stage, preferring a 
new collaborative strategy using novel iridium carbene species, which were emerging 
from the Kerr laboratory at the University of Strathclyde, Glasgow, UK. 
 
 
 
 
Phosphine N-Heterocyclic Carbene Complexes 
 
A range of relatively diverse iridium-based species have been utilised within labelling 
processes as depicted by the general reaction in Scheme 1, with each complex showing 
varying degrees of efficacy.27  Based on careful consideration of the steric and 
electronic characteristics of the associated ligand systems, it was believed that new 
iridium complexes, possessing a bulky N-heterocyclic carbene (NHC) and an 
appreciably encumbered phosphine, would potentially serve to mediate efficient HIE 
processes.  Additionally, if fully functionalised drug-like molecules of interest could be 
applied, this would also eliminate the need for any extra synthetic steps and avoid 
practical problems during reaction work-up and product isolation.  In relation to this, 
Nolan28 and Buriak29 have shown that complexes of the type 2 and 3, respectively 
(Figure 3), are useful as hydrogenation catalysts.  In particular, it has been noted that 
ligands of increasing bulk within species of type 3 may prevent the formation of inactive 
iridium clusters or promote the existence of active Ir-based monomeric species,29 in turn, 
leading to metal complex activation within the hydrogenation processes investigated. 
 
 
 
Figure 3.  Modified iridium complexes possessing an N-heterocyclic carbene ligand. 
 
Based on all of the above, initial efforts within the Kerr laboratories focused upon the 
preparation of iridium complexes with even greater steric demand around the metal 
centre.  The specific novel complexes which were targeted possessed the appreciably 
hindered NHC, 1,3-bis(2,4,6-trimethylphenyl)imidazol-2-ylidene (IMes), alongside the 
phosphines, PPh3, P(CH2Ph)3, and PMe2Ph. 
 
Preparation of the Targeted Novel Iridium Carbene Complexes 
 
In terms of access to the desired complexes, despite describing routes to related species, 
Buriak had been less successful in attempts to prepare compounds possessing both a 
relatively bulky phosphine and a more sterically-demanding NHC.29  In contrast, using 
in situ generation and introduction of the NHC ligand, in combination with a relatively 
non-coordinating solvent such as benzene in the initial steps, led to the delivery of the 
desired novel iridium complexes 4a, 4b, and 4c (Figure 4);30 since isolation and 
handling of the carbene ligand is avoided by the established synthetic strategy, no glove 
box techniques are required.  It is important to note, however, that the reaction solvents 
need to be dry and oxygen-free.  Each of the complexes is strongly red/orange-coloured 
and all are air- and moisture-stable solids.  The synthesis procedure for the preparation 
of the new carbene complexes is outlined in Scheme 2. 
 
 
 
Figure 4.  New iridium complexes possessing a sterically-demanding NHC and 
phosphine. 
 
 
Scheme 2.  General preparative route for the formation of the new iridium complexes. 
 
HIE Outcomes with the New Iridium Carbene Complexes 
 
When applied to a series of substrates, these robust and really very readily handled 
complexes, 4a-c, were shown to be highly active catalysts within directed HIE 
processes.  Indeed, these species revealed catalytic activity in such exchange processes 
far in excess of the industry standard, Crabtree’s catalyst, with excellent levels of 
labelling being achieved over short reaction times (< 90 min) and at very low metal 
complex loadings (down to 0.5 mol%).30  These catalysts also displayed the ability to 
perform selective labelling via a five-membered metallocyclic intermediate (5-mmi), 
over a six-membered metallocyclic intermediate (6-mmi).  One further practical benefit 
relates to the prolonged stability of these complex species; for example, following 
storage under an air atmosphere at room temperature for over 8 months, complex 4c 
remained significantly active in delivering 95% D incorporation (over both ortho-
positions) within N,N-diethyl para-toluamide after 16 h at room temperature in DCM (5 
mol% loading).30 
 
It should be noted at this stage that concurrent with the work in the Kerr laboratories, 
Powell et al. divulged the first use of Ir phosphine/NHC species in HIE processes, with 
the application of the Buriak IMe/PBun3 complex (3: R = Me; R’ = Bun).  Using this 
species at relatively high 2.2 equivalent (220 mol%) loadings, with a small range of 
substrates, provided levels of labelling which were equivalent to or better than those seen 
with 1 under equivalent conditions.31  When the same IMe/PBun3 catalyst was employed 
at appreciably lowered catalyst loadings of 5 mol% with acetophenone over 16 h, we 
observed significantly lowered levels of deuterium incorporation (<5% based on 
minimum levels of detection).30 
 
With specific regard to more drug-like or ADMET-related studies, Schemes 3, 4, and 5 
show a summary of results obtained from a series of further endeavours with the new 
iridium carbene catalysts.  In these studies standard hydrogen isotope exchange 
conditions were used with 2.5-5 mol% of the catalyst and 1 atmosphere of deuterium or 
tritium gas for the given reaction time.  As shown in Scheme 3, the sanofi-aventis 
antiandrogen, nilutamide, used for late-stage prostate cancer, is labelled to an excellent 
level of 98%D ortho to the nitro unit with only 2.5 mol% of catalyst 4c.32  In addition, 
this substrate also provides a further example of preferential labelling via a 5-mmi over a 
6-mmi, with only 6% and 12% D incorporation being observed at positions a and b, 
respectively. 
 
  
 
Scheme 3.  Labelling of nilutamide (sanofi-aventis) with complex 4c (2.5 mol%). 
 
Niclosamide, the Bayer AG anthelmintic agent, is a benzanilide derivative possessing 
hydroxyl, chloro, and nitro functionalities.  Based on the illustration in Scheme 4, 
positions a, b, and d are all expected to label via a 5-mmi, whereas position c would label 
through a 6-mmi, providing the potential for further selectivity.  Despite this, and the 
good percentages of D incorporation achieved over all four sites, the level of selectivity 
observed was really rather low with 5 mol% of complex 4a over 1 h at room 
temperature.32  Having stated this, it is worth noting that positions a and b, both of which 
are ortho to the nitro group, are not labelled to the same degree.  Indeed, the D uptake at 
position a, adjacent to both the nitro and chloro units, is 10% higher than at position b, 
suggesting that weak Ir ligation to the chloro unit enhances the directing effect for this 
position. 
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Scheme 4.  Labelling of niclosamide (Bayer AG) with complex 4a (5 mol%). 
 
Following the success of the new iridium carbene species for the incorporation of 
deuterium, we were keen to apply the same class of complexes in hydrogen-tritium 
exchange reactions to introduce this widely used radioactive label.  This has now been 
widely and successfully achieved in our laboratories.  As an example of this and as 
illustrated in Scheme 5, when N,N,4-trimethylbenzamide 5 was employed in conjunction 
with complex 4b (5 mol%), 31% of the sample possessed one tritium atom after only 2 h 
at room temperature.  As shown by the tritium-NMR in Figure 5, as anticipated, the 
tritium was incorporated into the aromatic ring (7.33 p.p.m.), with a small amount of 
tritium appearing within the amide methyl units at approx. 3 p.p.m.  In addition to this, 
due to the low catalyst loading and short reaction time, the tritium-NMR also shows this 
process to be extremely clean, with no tritiated by-products being observed. 
 
 
 
Scheme 5.  Tritiation of an amide substrate with complex 4b (5 mol%). 
 
 
 
Figure 5.  Tritium-NMR of the tritiated product from the reaction of amide 5 with 
complex 4b (Scheme 5). 
 
As is widely recognised, the production of tritiated impurities and by-products during the 
HIE process can lead to significant waste disposal problems.  In this respect, Figure 6 
shows a radiochromatogram of the crude reaction mixture from a tritiation of an 
AstraZeneca research compound when employing 100 mol% of Crabtree’s catalyst (as 
was standard in our laboratories in order to achieve acceptable levels of labelling).  As 
can be seen from the chromatogram, a plethora of radioactive materials have been 
produced, with only a very small peak corresponding to the tritiated compound of 
interest.  On the other hand, analysis of the crude reaction mixture carried out using a 
carbene catalyst 4c and the same AstraZeneca substrate shows a remarkable 
improvement (Figure 7).  Using only 5 mol% of the catalyst, a significantly enhanced 
quantity of the desired tritiated compound is obtained, whilst the reaction is exceedingly 
clean, with tritiated water as the only significant labelled by-product.  This large 
reduction in radioactive by-product formation is a clear advantage of these complexes 
when compared to Crabtree’s catalyst and could aid the pharmaceutical industry in 
managing waste issues, with benefits in terms of both disposal costs and environmental 
pollution.
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Figure 6.  Radiochromatogram from the crude reaction mixture following a tritiation 
with Crabtree’s catalyst (100 mol%). 
 
 
 
Figure 7.  Radiochromatogram from the crude reaction mixture following a tritiation 
with complex 4c (5 mol%). 
 
Comparison of the Iridium Carbene Catalysts with Crabtree’s Catalyst 
 
From the discussion in the preceding section, the advantages of the novel Kerr carbene 
catalysts over Crabtree’s catalyst 1 should be apparent in terms of labelling efficiencies 
at low catalyst loadings over short reaction times, exchange selectivities, and reaction 
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cleanliness.  In more specific terms, the high (and selective) HIE levels achieved with 
nilutamide with only 2.5 mol% of 4c over 1 h at room temperature (Scheme 3) can be 
directly compared to that observed with 1 under the same reaction conditions, where less 
than 6% labelling was obtained at each of the three sites in the molecule.  Similarly, 
under equivalent conditions to those detailed in Scheme 4, when Crabtree’s catalyst 1 
was employed with niclosamide less than 15% incorporation was obtained at positions a 
and d only. 
 
 
Conclusions 
 
As detailed here, this collaborative programme of work has revealed the considerable 
efficiency and general applicability of the specific group of novel iridium(I) complexes 
4a-c within iridium-catalysed C-H activation chemistry and hydrogen isotope exchange.  
The combined phosphine and bulky NHC ligands employed have led to catalysts which 
are highly active and which deliver high incorporations of deuterium or tritium into 
drug-like molecules, whilst tolerating a wide range of functional moieties.  Furthermore, 
catalyst loadings as low as only 0.5 mol% and short reaction times have been shown to 
provide extremely effective levels of labelling with a range of substrates. 
 
Iridium complexes 4a-c have also been applied within isotopic labelling endeavours as 
part of our drug development processes.  In this regard, the low catalyst loadings and 
short reaction times made possible by these new species have delivered tritiated products 
with very good levels of labelling and without any appreciable tritiated waste.  
Therefore, this emerging class of iridium catalysts have the clear potential to replace 
Crabtree’s catalyst 1 as the industry standard in this area. 
 
 
Experimental  
 
All syntheses of the catalysts were carried out under inert atmosphere in dry glassware.  
The screening reactions were carried out under a deuterium or carrier-free tritium 
atmosphere on a stainless steel manifold purchased from RC TRITEC AG, Teufen 
(Switzerland).  Deuterium gas was purchased from AGA (Sweden) and tritium gas was 
purchased from RC TRITEC AG.  All reagents were purchased from commercial 
suppliers (Sigma-Aldrich, Alfa Aesar or Strem) and were without further purification.  
The solvents use in catalyst preparation, tetrahydrofuran, diethyl ether and benzene, were 
dried by heating to reflux over sodium wire, using benzophenone ketyl as an indicator, 
and then distilled under nitrogen.  Dichloromethane was dried by heating to reflux over 
calcium hydride then distilled under nitrogen.  LC-MS was performed using an Agilent 
1100 series chromatograph on a Synergi Max RP column (3 x 50 mm, C12, 4 μ) with 
gradient elution (using a linear gradient of MeCN in H2O, pH = 4) with analysis via a 
Waters Micromass ZQ mass spectrometer with either APPI+ or ES+ ionisation.  
 
1H and 13C NMR spectra were recorded on a Bruker DPX 400 spectrometer at 400 MHz 
and 100 MHz, respectively.  Tritium-NMR spectra were recorded on a Varian Inova 500 
spectrometer at 534 MHz using a Nalorac 5 mm tritium probe with a double tuned coil 
for 1H/3H.  The incorporation of deuterium or tritium per molecule was determined by 
1H NMR or LC-MS and calculated with NAIC 1.2.33  
General preparation of the carbene catalysts 
 
An approximately 1M solution of sodium ethoxide was prepared by dissolving sodium 
metal (0.25 g) in ethanol (10 mL) in a previously flame-dried flask under argon. 
 
To a solution of η4-cycloocta-1,5-dieneiridium(I) chloride dimer, in dry benzene (10 
mL) in a previously flame-dried Schlenk tube under argon, was added the 1M sodium 
ethoxide solution and a colour change from orange to yellow was observed.  After 
stirring at room temperature for 10 minutes, 1,3-dimesitylimidazolium chloride was 
added as one portion and the solution was stirred under argon for 5 h.  After this time, 
the solvent was removed under high vacuum and the orange residue was triturated with 
dry diethyl ether (15 mL) and filtered through Celite under argon.  The solvent was 
concentrated in vacuo to yield a yellow solid which was dissolved in THF (15 mL) to 
give a yellow solution.  Addition of solid silver hexafluorophosphate caused a colour 
change to orange and this solution was stirred for 20 minutes, prior to filtration through 
Celite under argon.  To this orange solution was added the phosphine and the now deep 
red solution was stirred for 1-2 h.  After this time, the solvent was concentrated in vacuo 
and the product isolated by recrystallisation from DCM/diethyl ether. 
 
General HIE reaction conditions 
 
To a small round-bottomed flask was added the substrate and the iridium complex as a 
solution in dry dichloromethane (0.5 mL).  The flask was fitted to a TRITEC® manifold, 
immersed in a bath of liquid nitrogen, degassed using the freeze/thaw method, and was 
then filled with deuterium or tritium gas via the manifold.  The flask was removed from 
the bath and allowed to warm to room temperature and the reaction was allowed to stir 
vigorously at room temperature for the allotted reaction time.  After this time, the 
dichloromethane and any volatile deuterium or tritium was removed under a stream of 
nitrogen, and the flask refilled with methanol and evaporated (twice).  The catalyst 
complex was precipitated using diethyl ether and removed by filtration through a plug of 
silica.  Concentration of the filtrate under reduced pressure yielded the product which 
was analysed by 1H and tritium-NMR to determine the position (and extent) of labelling, 
and by LC/MS to determine the level of incorporation. 
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